Skip to main content
SpringerLink
Log in

Botulinum Toxin Injections for Neurogenic Thoracic Outlet Syndrome

  • Chapter
  • First Online:
Thoracic Outlet Syndrome

  • 128 Accesses

Abstract

Botulinum toxin (BTX) produces several effects that include muscular paralysis from temporary chemodenervation and modulation of pain neurotransmitters and autonomic nervous system. Because of these properties, BTX has been used to treat neuromuscular disorders including NTOS, autonomic disorders, and chronic pain. It also has effects beyond the neuromuscular junctions and synapses, so its exact mechanism of action in evaluating and treating NTOS is uncertain. In some cases, it has been used effectively for both the diagnosis and treatment of NTOS, and it has shown to be safe for this application. Further study is required to determine its precise role.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001;285(8):1059–70.

    Article  CAS  Google Scholar 

  2. Wheeler A, Smith HS. Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicology. 2013;306:124–46.

    Article  CAS  Google Scholar 

  3. Ishikawa H, Mitsui Y, Yoshitomi T, et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol. 2000;44(2):106–9.

    Article  CAS  Google Scholar 

  4. Seyler TM, Smith BP, Marker DR, et al. Botulinum neurotoxin as a therapeutic modality in orthopaedic surgery: more than twenty years of experience. J Bone Joint Surg Am. 2008;90(Suppl 4):133–45.

    Article  Google Scholar 

  5. Hofmann RJ. Treatment of Frey’s syndrome (gustatory sweating) and ‘crocodile tears’ (gustatory epiphora) with purified botulinum toxin. Ophthalmic Plast Reconstr Surg. 2000;16(4):289–91.

    Article  CAS  Google Scholar 

  6. Cordivari C, Misra VP, Catania S, Lees AJ. New therapeutic indications for botulinum toxins. Mov Disord. 2004;19(S8):S157–61.

    Article  Google Scholar 

  7. Schnider P, Binder M, Kittler H, et al. A randomized, double-blind, placebo-controlled trial of botulinum A toxin for severe axillary hyperhidrosis. Br J Dermatol. 1999;140:677–80.

    Article  CAS  Google Scholar 

  8. Laing TA, Laing ME, O’Sullivan ST. Botulinum toxin for treatment of glandular hypersecretory disorders. J Plast Reconstr Aesthet Surg. 2008;61(9):1024–8.

    Article  CAS  Google Scholar 

  9. Setler PE. Therapeutic use of botulinum toxins: background and history. Clin J Pain. 2002;18(6 Suppl):S119–24.

    Article  Google Scholar 

  10. Brin MF, Blitzer A, Stewart C, et al. Disorders with excessive muscle contraction: candidates for treatment with intramuscular botulinum toxin (“botox”). In: DasGupta BR, editor. Botulinum and tetanus neurotoxins. Boston, MA: Springer; 1993. p. 559–76.

    Chapter  Google Scholar 

  11. Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol. 2010;257(8):1330–7.

    Article  CAS  Google Scholar 

  12. Rosales RL, Chua-Yap AS. Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity. J Neural Transm. 2008;115(4):617–23.

    Article  CAS  Google Scholar 

  13. Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol. 1993;113(3):400–4.

    Article  CAS  Google Scholar 

  14. Mclellan K, Das REG, Ekong TAN, Sesardic D. Therapeutic botulinum type A toxin: factors affecting potency. Toxicon. 1996;34(9):975–85.

    Article  CAS  Google Scholar 

  15. Van Heest AE. Applications of botulinum toxin in orthopedics and upper extremity surgery. Tech Hand Up Extrem Surg. 1997;1(1):27–34.

    Article  Google Scholar 

  16. Willenborg MJ, Shilt JS, Smith BP, Estrada RL, Castle JA, Koman LA. Technique for iliopsoas ultrasound-guided active electromyography-directed botulinum a toxin injection in cerebral palsy. J Pediatr Orthop. 2002;22(2):165–8.

    PubMed  Google Scholar 

  17. Torriani M, Gupta R, Donahue DM. Botulinum toxin injection in neurogenic thoracic outlet syndrome: results and experience using a ultrasound-guided approach. Skelet Radiol. 2010;39:973–80.

    Article  Google Scholar 

  18. Sarifakioglu N, Sarifakioglu E. Evaluating the effects of ice application on the pain felt during botulinum toxin type-a injections: a prospective, randomized, single-blind controlled trial. Ann Plast Surg. 2004;53(6):543–6.

    Article  Google Scholar 

  19. Eames NW, Baker R, Hill N, Graham K, Taylor T, Cosgrove A. The effect of botulinum toxin A on gastrocnemius length: magnitude and duration of response. Dev Med Child Neurol. 1999;41(4):226–32.

    Article  CAS  Google Scholar 

  20. Administration USF and D. Early communication about an ongoing safety review botox and botox cosmetic (botulinum toxin type A) and myobloc (botulinum toxin type B). Plast Surg Nurs. 2008;28(3):150–1.

    Google Scholar 

  21. BOTOX®. Cosmetic (botulinum toxin type A) purified neurotoxin complex. Package insert. Irvine, CA: Allergan Inc; 2002.

    Google Scholar 

  22. Demondion X, Herbinet P, Van Sint JS, Boutry N, Chantelot C, Cotten A. Imaging assessment of thoracic outlet syndrome. Radiographics. 2006;26(6):1735–50.

    Article  Google Scholar 

  23. Christo PJ, McGreevy K. Updated perspectives on neurogenic thoracic outlet syndrome. Curr Pain Headache Rep. 2011;15(1):14–21.

    Article  Google Scholar 

  24. Jordan SE, Ahn SS, Gelabert HA. Combining ultrasonography and electromyography for botulinum chemodenervation treatment of thoracic outlet syndrome: comparison with fluoroscopy and electromyography guidance. Pain Physician. 2007;10(4):541–6.

    PubMed  Google Scholar 

  25. Jordan SE, Ahn SS, Freischlag JA, Gelabert HA, Machleder HI. Selective botulinum chemodenervation of the scalene muscles for treatment of neurogenic thoracic outlet syndrome. Ann Vasc Surg. 2000;14(4):365–9.

    Article  CAS  Google Scholar 

  26. Jordan SE, Ahn SS, Gelabert HA. Differentiation of thoracic outlet syndrome from treatment-resistant cervical brachial pain syndromes: development and utilization of a questionnaire, clinical examination and ultrasound evaluation. Pain Physician. 2007;10(3):441–52.

    PubMed  Google Scholar 

  27. Lum YW, Brooke BS, Likes K, et al. Impact of anterior scalene lidocaine blocks on predicting surgical success in older patients with neurogenic thoracic outlet syndrome. J Vasc Surg. 2012;55(5):1370–5.

    Article  Google Scholar 

  28. Torriani M, Gupta R, Donahue DM. Sonographically guided anesthetic injection of anterior scalene muscle for investigation of neurogenic thoracic outlet syndrome. Skelet Radiol. 2009;38:1083–7.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Thoracic Surgery, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    Dean M. Donahue

  2. Division of Musculoskeletal Imaging and Intervention, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    Martin Torriani

Authors
  1. Dean M. Donahue
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin Torriani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dean M. Donahue .

Editor information

Editors and Affiliations

  1. Vascular Surgeon, Charleston, SC, USA

    Karl A. Illig

  2. Center for Thoracic Outlet Syndrome and Section of Vascular Surgery, Washington University School of Medicine and Barnes-Jewish Hospital, Saint Louis, MO, USA

    Robert W. Thompson

  3. Wake Forest Baptist Health, Wake Forest School of Medicine, Atrium Health, Department of Vascular and Endovascular Surgery, Winston-Salem, NC, USA

    Julie Ann Freischlag

  4. Department of Thoracic Surgery, Massachusetts General Hospital Department of Thoracic Surgery, Boston, MA, USA

    Dean M. Donahue

  5. Neurological Associates, The Interventional Group, Santa Monica, CA, USA

    Sheldon E. Jordan

  6. Division of Vascular Surgery and Endovascular Therapy, Johns Hopkins School of Medicine, Baltimore, MD, USA

    Ying Wei Lum

  7. UCLA Medical Center, Los Angeles, CA, USA

    Hugh A. Gelabert

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Donahue, D.M., Torriani, M. (2021). Botulinum Toxin Injections for Neurogenic Thoracic Outlet Syndrome. In: Illig, K.A., et al. Thoracic Outlet Syndrome. Springer, Cham. https://doi.org/10.1007/978-3-030-55073-8_36

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-55073-8_36

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-55072-1

  • Online ISBN: 978-3-030-55073-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation